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Abstract 
Background 
Haemorrhage is the leading cause of death during trauma. In 2012, London's Air 
Ambulance introduced Blood on Board (BOB), transfusing group O red cells 
(RBC) to trauma patients at the scene.  
Objectives 
This study assessed the impact of BOB on: the number of mixed field samples 
received by the laboratory; the number of group O RBC transfused to non-group 
O patients; and the ratio of RBC to fresh frozen plasma (FFP) transfused in the 
initial 24 hours.  
Methods 
Three Major Trauma Centres collected data on patients for whom the major 
haemorrhage protocol was activated between August 2008-February 2012, pre-
BOB, and March 2012-December 2013, post-BOB.  
Results 
 233 trauma patients were identified pre-BOB and 119 post-BOB. There was no 
significant difference in the percentage of Group O units transfused to non-group 
O patients (75 vs. 82%, p=0.21) or the RBC:FFP ratio (pre-BOB mean 1.6 [IQR 
1.0-2.0]; post-BOB mean 1.7 [IQR 1.1-2.2], P = 0.24). There was no significant 
difference in the percentage of mixed field samples received (23% v 27%, p=0.3).  
Conclusion 
 The introduction of BOB did not change the proportion of group O RBC 
transfused or the RBC:FFP ratio, however, the proportion of acceptable samples 
decreased. This is largely due to an increase in blood samples not received from 
the post-BOB cohort, which we believe is probably due to patients who died at 
the scene. We have introduced robust systems to indicate reasons for not 
obtaining samples. 
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Introduction 
 
Trauma is one of the world’s leading causes of death, accounting for up to 5 
million deaths per year (Haagsma et al, 2015). Uncontrolled post-traumatic 
haemorrhage is the leading cause of death in these patients (Cothren et al, 2007) 
and for this reason a timely and organised approach to the management of 
bleeding is crucial to improving clinical outcomes. 
 
Observational studies in military and civilian trauma bleeding patients have 
indicated that transfusion of high ratios of plasma to red blood cells units (RBC) 
may improve morbidity and mortality although the quality of the evidence for 
this so far is low (Murad et al, 2010). The recent PROPPR trial showed a 
reduction in early exsanguination with a higher plasma to RBC ratio (Holcomb et 
al, 2015). Current guidelines therefore recommend that fresh frozen plasma 
(FFP) should be given upfront during major haemorrhage of trauma and that the 
initial FFP to RBC ratio should be 1:1 (Hunt et al, 2015).  In order to allow for the 
early delivery of blood components during major haemorrhage, most hospitals 
have now established major haemorrhage protocols (MHP) as part of damage 
control resuscitation and studies have demonstrated that MHP improve 
administration of blood components and reduce wastage (Khan et al, 2013). 
Other measures, such as the use of tranexamic acid are also part of MHP to 
optimise haemorrhage control (Shakur et al, 2010). 
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In the pre-hospital setting, when compared to crystalloid resuscitation alone, 
early transfusion with RBC and plasma improves early outcomes although did 
not have an effect on 30-day mortality (Holcomb et al, 2014). However the 
impact of pre-hospital transfusion on laboratory practice is unknown. Blood 
transfusion prior to group and screen (G&S) testing may result in a mixed field 
reaction, requiring further testing, and in the case of urgent transfusion, the use 
of Group O units until investigations can be fully resolved (Milkins et al, 2013). 
 
In March 2012, the London's Air Ambulance (LAA) started carrying Group O 
negative RBC for on-scene transfusion to trauma patients in an initiative known 
as Blood on Board (BOB).  The aims of this study were to assess the impact of this 
on laboratory practice as examined by the number of mixed field samples 
received, the numbers of Group O RBC transfused to non-group O patients and 
the RBC: FFP ratios. 
 
Methods 
 
The London Trauma Network was established in 2008 to provide specialist and 
co-ordinated care to major trauma patients across the region, and to collect data 
for the purposes of audit and research. Patients are seen by LAA and then 
transferred to one of the designated major trauma centres.  During the study 
period, these trauma centres used the same MHP. Group O units were given 
before a blood group was established. One hospital within the London Trauma 
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Network uses group O positive RBC units for male patients and group O negative 
RBC for female patients. The other trauma centres administer group O negative 
RBC for all patients.  Data were collected from August 2008 to February 2012 
(pre-BOB) and from March 2012 until September 2013 (post-BOB) on all 
patients for whom the MHP was activated. Data were collected from LAA trauma 
office records and hospital transfusion laboratories. Information obtained 
included demographic data, the number of RBC units transfused by LAA and 
destination of the patient (including death at the scene), and laboratory data, 
including group and screen results. The number of group-O and group-specific 
RBC transfused was recorded in addition to the number of other blood 
components issued in the first 24 hours from the time of arrival at hospital.   
 
Group and screen samples 
All group and screen (G&S) samples were taken in EDTA anticoagulated bottles 
and labelled with handwritten unique trauma identifiers according to hospitals’ 
standard operating procedure. Samples were analysed as priority on arrival to 
the laboratory. Samples taken in the post-BOB group in patients who 
subsequently died at the scene were also taken to the laboratory. 
 
ABO and RhD typing was determined by a microplate haemagglutination 
technique in Centre A (Immucor-NEO, Immucor Inc, GA, USA) and gel card 
technique in Centres B and C (DiaMeD ID-System, BioRad Laboratories, BioMed 
GbmH, Switzerland). Mixed field samples were defined as those whose blood 
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group could not be resolved by automation. For those patients who had a mixed 
field result detected by automation method, manual testing using the DiaMeD 
system was performed.  
 
Inadequately labelled samples were defined as those where the sample did not 
meet the identification criteria required by the laboratory policy.  
 
Statistical analysis 
Statistical analysis was performed using Stata 12 software (StataCorp. 2011. 
Stata Statistical Software: Release 12. College Station, TX: StataCorp LPv). The 
results are expressed as mean, median, ratio and percentage. Comparisons 
between groups were made using the un-paired ‘Mann-Whitney’ test for not 
normally distributed data and t-test for normally distributed data. A 2-tailed p 
value of <0.05 was considered statistically significant.  
 
Results 
 
Between August 2008 and February 2012, we identified 352 patients in whom 
MHP was activated. Of these, 233 patients presented pre-BOB and 119 presented 
post-BOB. Their demographic data and blood components received are 
described in Table 1. The median age was 30 in the pre-BOB group (IQR 23-42) 
and 35 (IQR 23-51) in the post-BOB group.    
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In the pre-BOB group, 202 patients (87%) received a transfusion of any blood 
component. There was 100% traceability and no wastage.  In the post-BOB 
group, 119 patients received a transfusion (100%) as part of BOB, and 83 
patients (70%) received a subsequent transfusion of any blood components in 
hospital.  Of the 36 patients not receiving any further transfusions after BOB, this 
included the 15 patients who died on the scene, but also 21 patients who did not 
require further transfusion in hospital.  
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Table 1. Demographics of patients and total amount of blood transfusion  
  Pre-BOB 
N=233 (%) 
Post-BOB 
N=119 (%) 
Gender Male 
Female 
Unknown 
188 (81) 
45 (19) 
0 (0) 
84 (71) 
32 (27) 
3 (3)* 
Age in years (IQR) 30 (23-42)  35 (23-51) 
Destination Trauma centres 
(total) 
- Trauma 
Centre A 
- Trauma 
Centre B 
- Trauma 
Centre C 
 
Died on scene 
 
229 (98) 
 
171 (73) 
 
33 (14) 
 
25 (11) 
 
 
4 (2) 
104 (87) 
 
77 (65) 
 
19 (16) 
 
7 (6) 
 
 
15 (13)** 
Blood 
group 
Known 
Unknown 
Group O (% of 
known) 
Non-group O (% 
of known) 
201 (86) 
32 (14) 
93 (46) 
 
108 (54) 
80 (67) 
39 (33) 
37 (46) 
 
43 (54) 
 
 
Blood Components issued (range) 
Mean blood 
components 
transfused 
in first 24 
hours per 
patient  
Total RBC units 10 (0-67) 9 (1-63) 
-RBC given by 
LAA post-BOB 
n/a 2 (1-4) 
FFP 6  (0-49) 5 (0-31) 
Cryoprecipitate 1 (0-17) 1 (0-17) 
Platelets 1 (0-10) 1 (0-6) 
BOB: blood on board; IQR: interquartile range; RBC: red blood cells; FFP: fresh frozen plasma. 
* Due to rounding, the total % adds up to >100.  
**p<0.001 
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The mean (standard deviation) RBC to FFP ratio was 1.6 (0.8) in the pre-BOB 
group and 1.7 (0.8) in the post-BOB. There was no significant difference between 
the two groups (mean difference 0.13, 95% confidence interval 0.36–0.92).  59% 
of the pre-BOB patients and 42% of the post-BOB patients had an RBC to FFP 
ratio of 2:1 or less.  
 
Results of group and screen samples (G&S) are described in Table 2.  There was 
no significant difference in the percentage of mixed field samples pre-BOB vs. 
post-BOB (p=0.3). 
 
Table 2. Group and screen samples  
 Pre-BOB 
N=233 
N (%) 
Post-BOB 
N=119 
N  (%) 
Mixed field 53 (23) 32 (27) 
 
No sample received 
 
 
30 (13) 
 
 
37 (31) 
 
Inadequate labelling 
 
3 (1) 6 (5) 
Acceptable 147 (63) 44 (37) * 
 *p < 0.001 (pre vs. post BOB)  
BOB: blood on board  
 
An analysis of group O units transfused to non-group O patients was performed 
and this is shown in table 3. There were 97 patients with a known non-Group O 
blood group who received a transfusion of RBC in the pre-BOB group and 43 in 
the post-BOB group. Patients who did not receive any transfusion were excluded 
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from analysis. The mean total number of RBC, mean total Group O units and the 
proportion of total units given as Group O are shown in table 3. There was no 
significant difference in the number of total RBC (p=0.17), number of Group O 
RBC (p=0.29) or the percentage of total units given that were group O (p=0.21). 
Patients were also categorised into those who received >95% of their total units 
as group O units or <95% group O RBC due to the wide range in the total number 
of units of RBC given and the difference in mean units given between the pre-
BOB and post-BOB groups.   
 
Table 3. Group O RBC transfused to non-group O patients in first 24 hours 
 
Mean total 
units RBC  
Mean 
Group O 
units RBC 
Group O 
units/Total 
units (%) 
Pre-BOB  
N=97 
13 9 75 
Post-BOB 
N=43 
10 7 82 
 Group O 
units/total 
units 
<95% 
Group O 
units/total 
units >95% 
Total 
Pre-BOB (N) 
% 
 
50 47 97 
52% 48% 100% 
    
Post-BOB (N) 
% 
25 18 43 
58% 42% 100% 
   
RBC: red blood cells; BOB: blood on board  
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Discussion 
 
In this study we have shown that following the introduction of BOB, there has 
been no significant difference in the proportion of mixed field samples received 
by the laboratory (23% vs. 27%), suggesting that, post-BOB, G&S samples are 
being taken according to protocol, i.e. before transfusion. In addition, we have 
demonstrated that there is no increase in the percentage of group O-units 
transfused to non-group O patients and no change in RBC: FFP ratios. These 
findings are reassuring as they suggest that BOB is safe, does not lead to 
increased usage of Group O units and is unlikely to significantly impact the 
laboratory workload.  Although there is a decrease in what is deemed an 
acceptable sample, it is likely that this is largely due to fewer G&S samples being 
sent from severely injured patients who died either at the scene of the incident 
or just before arrival in hospital in the pre-BOB era, as there would not have 
been an indication to send samples until arrival at the trauma centre. Other 
possible reasons for a decrease in acceptable samples include: failure to obtain 
G&S sample prior to initiation of blood transfusion at the scene of the incident 
post-BOB; inappropriate labelling of blood samples leading to rejection by the 
laboratories; or G&S samples being lost in the Emergency Department (due to 
chaotic nature of the situation) and not being sent to laboratories. We believe 
that the first reason is the most likely explanation, as the teams managing these 
patients both pre- and post- BOB have remained largely the same, although we 
note the small increase in inadequate labelling, which may be due to increased 
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workload at the scene, and this is being addressed with LAA teams. We note that 
results in mixed field results can vary depending on the technology used (UK 
NEQAS, 2016); however the technologies used were consistent in each centre 
across the course of the study and as the proportion of patient numbers from 
each centre was largely similar both pre-and post-BOB, we would not expect this 
to have significant impact on the proportion of mixed field samples received.  
 
 We also note the increase in number of patients recorded to have died at the 
scene; however due to the incomplete nature of the documentation, this was not 
always recorded and it is possible that this is an underrepresentation of the true 
figure, particularly in the pre-BOB group, as in the post-BOB group, death at 
scene was often recorded on the blood traceability form. This study was not 
powered to look for changes in mortality; however this is clearly something that 
needs further investigation in subsequent research. 
 
It can be anticipated that the increase in unacceptable or missing samples would 
lead to an increase in the workload for transfusion staff (as there will be more 
frequent need to contact clinical teams to request another G&S sample), and this 
could have an impact on other valuable transfusion services. Ideally G&S samples 
should be taken at the time of intravenous cannulation by the LAA team prior to 
transfusion; however it is acknowledged that in some cases this will not be 
possible for clinical or practical reasons, and the priority must be early 
transfusion of blood components. Following the results of this study we have 
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introduced a G&S sample box which is sent to the laboratory together with the 
transfusion paperwork even in the event of patient death at the scene; if G&S 
sample is not taken, the clinical team must indicate the reasons for not including 
it.  
 
Two important and interesting findings are those regarding the ratio of group O-
units to non-group O patients, and the RBC: FFP ratios. There was no significant 
increase in the proportion of group O units issued to non-group O patients. The 
most likely reason for this is the availability and accessibility of remote issue for 
group O RBC units in emergency departments and operating theatres resulting in 
their high use both pre and post-BOB. In the acute setting, it is very likely that 
clinicians are not aware when patients can be switched to group specific RBC, 
and we are implementing systems to ensure that laboratory staff inform clinical 
teams when Group-specific blood is available, in order to reduce inappropriate 
transfusion of group O RBC. The ratio of RBC: FFP did not change between the 
two groups following the introduction of BOB. This is reassuring and can be 
explained by the fact that introduction of MHP in most trauma centres allows for 
FFP to be issued upfront, as soon as the major haemorrhage protocol is activated, 
and we are considering the introduction of thawed plasma to the BOB packs. 
Although the rate was higher than the current recommendation of 1:1, it is 
consistent with the then recommended ratio of 6:4 which was part of the MHP 
used at the time, and we expect it to change in light of the new guidelines. 
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In conclusion, BOB appears to have led to an increase in the proportion of 
unacceptable G&S samples. This is likely to be due to an increase in cases in 
which no sample was received (probably due to the capture of patients dying at 
the scene in the post-BOB cohort). However, the proportion of Group O RBC 
issued to non group O patients has not significantly increased; this is because 
almost half of non-group O patients in both the pre and post-BOB groups are 
receiving >95% group O RBC in the initial 24 hour period, even when patient’s 
blood group is known. More work needs to be done to improve communication 
between pre-hospital and laboratory teams in order to optimise the quality of 
G&S samples received; this will enable patients to receive the most appropriate 
blood components as quickly as possible. The most efficient strategies for doing 
this need to be identified and the impact on laboratory and clinical outcomes 
measured. The BOB project is still in its early days; with increasing awareness 
and education this can be improved.  
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